Spatial analyses implicate high stromal tumour-infiltrating CD8<sup>+</sup> lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer
Female patients with ER<sup>+</sup>HER2<sup>-</sup> breast cancer have a favourable prognosis for 5-10 years. Later relapses are, however, common, yet predictions of late recurrence risk are suboptimal, particularly for patients with intermediate risk determined by the …
Read PDF